Neuropathology in multiple sclerosis: New concepts

Multiple Sclerosis

Volumn 4, Issue 3, 1998, Pages 93-98

  Lassmann, Hans ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Axon; Demyelination; Multiple sclerosis; Oligodendrocyte; Pathology

Indexed keywords

ANTIBODY; ENCEPHALITOGENIC PROTEIN;

ARTICLE; CELL DESTRUCTION; CELL METABOLISM; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; DEMYELINATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; INFLAMMATION; MACROPHAGE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE REGENERATION; NEUROPATHOLOGY; OLIGODENDROGLIA;

EID: 0031684646     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400301     Document Type: Article

References (74)

1. Marburg O. (1906) Die sogenannte 'akute Multiple Sklerose' Jahrb Psychiatrie 27: 211-312.
2. Lassmann H. (1997) Multiple sclerosis pathology. In: A. Compston (Ed) McAlpine's Multiple Sclerosis, 3rd Edition; Churchill Livingstone in press.
3. Losseff NA et al. (1996) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119: 701-708.
4. Lassmann H. (1983) Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Schriftenr Neurol 25: 1-35.
5. Prineas JW et al. (1993a) Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33: 137-151.
6. Schlesinger H. (1909) Zur Frage der akuten multiplen Sklerose und der encephalomyelitis disseminata im Kindesalter. Arb Neurol Inst (Wien) 17: 410-432.
7. Dévie C. (1994) Myélite subaigue compliquée de névrite optique. Bull Med 8: 1033.
8. Balo J. (1928) Encephalitis periaxialis concentrica. Arch Neurol 19: 242-264.
9. Schilder P. (1912) Zur Kenntnis der sogenannten diffusen Sklerose (über Encephalitis periaxialis diffusa). Z Gesamt Neurol Psychiatr 10: 1-60.
10. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6: 259-274.
11. Haines JL et al. (1996) A genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The multiple sclerosis genetics group. Nature Genetics 13: 469-471.
12. Sawcer S et al. (1996) A genomic screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics 13: 464-468.
13. Ebers GC et al. (1996) A full genome search in multiple sclerosis. Nature Genetics 13: 472-476.
14. Traugott U, Reinherz EL, Raine CS. (1983) Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 4: 201-221.
15. Esiri MM. (1977) Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 2: 478-480.
16. Newcombe J, Li H, Cuzner ML. (1994) Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Apll Neurobiol 20: 152-162.
17. Ulvestad E et al. (1994) Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 121: 125-131.
18. Brück W et al. (1995) Monocyte/macrophage differentiation in early multiple sclerosis. Ann Neurol 38: 788-796.
19. Washington R et al. (1994) Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 35: 89-97.
20. Cannella B, Raine CS. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
21. Wucherpfenning KW et al. T-cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. J Exp Med 175: 993-1002.
22. Woodroofe MN, Cuzner ML. (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by nonradioactive in situ hybridization. Cytokine 5: 583-588.
23. Ben-Nun A, Wekerle H, Cohen IR. (1981) The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 11: 195-199.
24. Berger T et al. (1997) Experimental autoimmune encephalomyelitis: The antigen specificity of T-lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 76: 97-108.
25. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130: 443-454.
26. Lassman H, Brunner C, Bradl M, Linington C. (1988) Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol 75: 566-576.
27. Linington C, Engelhardt B, Kapocs G, Lassmann H. (1992) Induction of persistently demyelinating lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibodies. J Neuroimmunol 40: 219-224.
28. Amor S et al. (1994) Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 153: 4349-4356.
29. Adelmann M et al. (1995) The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 63: 17-27.
30. Johns TG et al. (1995) Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 154: 5536-5541.
31. Bornstein MB, Appel SH. (1965) Tissue culture studies of demyelination. Ann NY Acad Sci 122: 280-286.
32. Grundke Iqbal I, Bornstein MB. (1980) Multiple sclerosis: serum gamma globulin and demyelination in culture. Neurology 30: 749-754.
33. Prineas JW, Graham JS (1981) Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 10: 149-158.
34. Gay D, Esiri M. (1991) Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytochemical study. Brain 114: 557-572.
35. Hafler DA, Weiner HL. (1995) Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 144: 75-107.
36. Genain CP et al. (1996) Late complications of immune deviation therapy in a nonhuman primate. Science 274: 2054-2057.
37. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. (1995) Differential susceptibility of human CNS-derived cell populations to TNF dependent and independent immune-mediated injury. J Neurosci 15: 7293-7300.
38. Freedman MS, Ruijs TC, Selin LK, Antel JP. (1991) Peripheral blood gamma/delta T cells lyse fresh human brain derived oligodendrocytes. Ann Neurol 30: 794-800.
39. Selmaj K et al. (1991b) Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 147: 1522-1529.
40. Scolding N, Jones J, Compston DA, Morgan BP. (1990) Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology 70: 6-10.
41. D'Souza SD et al. (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184: 2361-2370.
42. + oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 88: 6452-6456.
43. van Noort JM et al. (1995) A novel candidate autoantigen in multiple sclerosis: αB-crystallin, a small heat shock protein. Nature 375: 798-801.
44. Dowling P et al. (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184: 1513-1518.
45. Scolding NJ et al. (1989). Normal rat serum cytotoxicity against syngeneic oligodendrocytes: Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci 89: 289-300.
46. Griot C et al. (1990) Selective degeneration of oligodendrocytes mediated by reactive oxygen species. Free Radic Res Commun 11: 181-193.
47. Selmaj KW, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
48. Probert L et al. (1995) Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor a. Proc Natl Acad Sci USA 92: 11294-11298.
49. Hofman FM, Hinton DR, Johnson K, Merrill JE. (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612.
50. Selmaj K, Raine CS, Cannella B, Brosnan CF. (1991c) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87: 949-954.
51. Rosenthal A, Fujinami RS, Lampert PW. (1986) Mechanisms of Theiler's virus induced demyelination in nude mice. Lab Invest 54: 515-522.
52. Jordan CA et al. (1989) Expression of viral and myelin gene transcripts in a murine CNS demyelinating disease caused by a coronavirus. Glia 2: 318-329.
53. Rodriguez M, Prayoonwiwat N, Howe C, Sanborn K. (1994) Proteolipid protein gene expression in demyelination and remyelination of the central nervous system: a model for multiple sclerosis. J Neuropath Exp Neurol 53: 136-143.
54. Barac-Latas et al. (1997) Patterns of oligodendroglia pathology in corona virus induced subacute demyelinating encephalomyelitis in the Lewis rat. Glia 19: 1-12.
55. Readhead C, Schneider A, Griffiths I, Nave KA. (1994) Premature arrest of myelination in transgenic mice with increased proteolipid protein gene dosage. Neuron 12: 583-595.
56. Kagawa T et al. (1994) Glial cell degeneration and hypomyelination caused by overexpression of the myelin proteolipid gene. Neuron 13: 427-442.
57. Montag D et al. (1994) Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13: 229-246.
58. Lassmann H, Bartsch U, Montag D, Schachner M. (1997) Dying back oligodendrogliopathy: A late sequal of myelin-associated glycoprotein deficiency. Glia 19: 104-110.
59. Challoner PB et al. (1995) Plaque associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 92: 7440-7444.
60. Gendelman HE et al. (1985) A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann Neurol 18: 324-328.
61. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ (1993) Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 68: 627-636.
62. Ozawa K et al. (1994) Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117: 1311-1322.
63. Lassmann H, Suchanek G, Ozawa K. (1994) Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 36: S42-S46.
64. Brück W et al. (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol in press.
65. Heyes MP, Saito K, Markey SP. (1992) Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 283: 633-635.
66. Olney JW. (1983) Excitotoxins: an overview. In: K Fuxe, P Roberts and R Schwarcz (Eds). Excitotoxins Macmillan: London. 82-96.
67. Chou SM, Wang HS, Taniguchi A. (1996) Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. J Neurol Sci 139: 16-26.
68. Raine CS, Scheinberg L, Waltz JM. (1981) Multiple sclerosis: Oligodendrocyte survival and proliferation in an active established lesion. Lab Invest 45: 534-546.
69. Prineas JW, Kwon EE, Cho ES, Sharer LR. (1984) Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann NY Acad Sci 436: 11-32.
70. Brück W et al. (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 35: 65-73.
71. Targett MP et al. 1996) Failure to achieve remyelination of demyelinated rat axons following transplantation of gloal cells obtained from the adult human brain. Neuropathol Appl Neurobiol 22: 199-206.
72. Prineas JW et al. (1993b) Multiple sclerosis. Pathology of recurrent lesions. Brain 116: 681-693.
73. Miller DJ, Asakura K, Rodriguez M. (1996). Central nervous system remyelination. Clinical application of basic neuroscience principles. Brain Pathol 6: 331-344.
74. Storch MK et al. (1998) Multiple sclerosis: In situ evidence for antibody - and complement mediated demyelination. Ann Neurol 43: 465-471.